| Program | Indication | Preclinical | cmc | Phase 1 | Phase 2 | Phase 3 | Rights | |||
|---|---|---|---|---|---|---|---|---|---|---|
| GI INFLAMMATION AND IMMUNOLOGY | ||||||||||
| VE202 | Mild-to-Moderate Ulcerative Colitis |
Preclinical Phase
complete
|
cmc Phase
complete
|
Phase 1 Phase
complete
|
Phase 2 Phase
in progress
|
Phase 3 Phase
not started
|
|
|||
| GI INFECTION PREVENTION | ||||||||||
| VE303 | Recurrent C. difficile Infection |
Preclinical Phase
complete
|
cmc Phase
complete
|
Phase 1 Phase
complete
|
Phase 2 Phase
complete
|
Phase 3 Phase
in progress
|
|
|||
| VE707 | Gram-negative AMR Infections |
Preclinical Phase
complete
|
cmc Phase
in progress
|
Phase 1 Phase
not started
|
Phase 2 Phase
not started
|
Phase 3 Phase
not started
|
|
|||
|
CMC: chemistry, manufacturing and controls; AMR: antimicrobial-resistant |
||||||||||